A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

BACKGROUND: Interleukin-6 (IL-6) transduces signals via phosphorylation of STAT3 (pSTAT3). Tocilizumab (TCZ) is an IL-6 receptor blocker, which, when administered intravenously every 4 weeks, efficiently ameliorates rheumatoid arthritis (RA). Since IL-6 signal strength varies among patients with RA,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arthritis Res Ther
Auteurs principaux: Saito, Shuntaro, Suzuki, Katsuya, Yoshimoto, Keiko, Kaneko, Yuko, Matsumoto, Yoshihiro, Yamaoka, Kunihiro, Takeuchi, Tsutomu
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5645925/
https://ncbi.nlm.nih.gov/pubmed/29041951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1434-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires